Myeloproliferative Neoplasms: Critical Concepts and Management

Description

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field. Front Matter....Pages i-viii Front Matter....Pages 1-1 Update on the Biology of Myeloproliferative Neoplasms....Pages 3-10 Do We Need Biological Studies for Patient Management?....Pages 11-16 Front Matter....Pages 17-17 Critical Issues About the Diagnosis of MPNs: Bone Marrow Histopathology....Pages 19-35 Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification....Pages 37-45 Patient’s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms....Pages 47-55 Mechanisms of Thrombogenesis....Pages 57-67 Front Matter....Pages 69-69 Risk Classification....Pages 71-84 Goal of Therapy and Monitoring the Response in Polycythemia Vera and Essential Thrombocythemia....Pages 85-92 First-Line Therapy and Special Issues Management in Polycythemia Vera and Essential Thrombocythemia....Pages 93-104 Primary and Secondary Antithrombotic Prophylaxis....Pages 105-118 Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options....Pages 119-129 Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms....Pages 131-145 Front Matter....Pages 147-147 Current Clinical Needs....Pages 149-161 Risk Stratification in PMF....Pages 163-175 Nontransplant Treatment Options for Myelofibrosis: How to Treat Anemia, Splenomegaly, Constitutional Symptoms, and Extramedullary Disease....Pages 177-186 Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis....Pages 187-199 Front Matter....Pages 201-201 A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy....Pages 203-214 Ongoing Clinical Trials in Myeloproliferative Neoplasms....Pages 215-232 Back Matter....Pages 233-240